HBIO’s Market Quandary: Decoding the Ups and Downs of 2025

The stock price performance over the year has been a mixed bag, resulting in a range of outlooks from optimistic to pessimistic depending on the observer. This year’s metric has recorded a Price decrease of -82.83%. However, over the past six months, we’ve seen a stronger performance of -66.74%. The price of HBIO fallen by 7.71% over the last 30 days. And in the last five days, it has surged by 10.09%.

The stock price for Harvard Bioscience Inc (HBIO) currently stands at $0.48. The stock experienced a substantial increase in the last session, hitting $3.0 after starting at $0.48. The stock’s lowest price was $3.0 before closing at $0.53.

Harvard Bioscience Inc experienced a somewhat shaky performance in the stock market. The company’s stock reached a 1-year high of $3.27 on 08/26/24, while the lowest price for the same period was registered at $0.28 on 05/28/25.

52-week price history of HBIO Stock

Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. Harvard Bioscience Inc’s current trading price is -85.35% away from its 52-week high, while its distance from the 52-week low is 70.28%. The stock’s price range during this time has been between $0.28 and $3.27. The trading volume for the Healthcare sector company’s shares reached about 0.91 million for the day, which was lower than the average daily volume of 12.15 million over the last three months.

Market Capitalization vs. Financial Performance: A Comparative Study

Harvard Bioscience Inc (HBIO) has experienced a quarterly rise of 52.06% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 21.18M and boasts a workforce of 355 employees.

Combining Moving Average and Trading Volume Data for Better Market Insight

Based on Barchart.com data, the company’s moving average over the 100-day period was 0.4518, with a change in price of -0.1947. Similarly, Harvard Bioscience Inc recorded 7,782,126 in trading volume during the last 100 days, posting a change of -28.90%.

HBIO’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look

The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for HBIO stands at 2.22. Similarly, the long-term debt-to-equity ratio is also 0.46.

HBIO Stock Stochastic Average

Today’s raw stochastic average for Harvard Bioscience Inc over the last 50 days is 39.21%.This indicates a increase from the raw stochastic average of the past 20 days, which was 36.64%. Moreover, the company’s Stochastic %K and %D values for the last 20 days were 47.65% and 47.94%, respectively.

Invest Chronicle
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.